Compare HROW & SECZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HROW | SECZ |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2008 | 2026 |
| Metric | HROW | SECZ |
|---|---|---|
| Price | $28.30 | $8.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $62.63 | $15.66 |
| AVG Volume (30 Days) | 635.5K | ★ 2.4M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.13 | $17.10 |
| Revenue Next Year | $56.02 | $66.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.76 | $5.14 |
| 52 Week High | $54.98 | $17.00 |
| Indicator | HROW | SECZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 47.77 |
| Support Level | $27.75 | $5.86 |
| Resistance Level | $30.28 | $17.00 |
| Average True Range (ATR) | 1.66 | 0.77 |
| MACD | 0.31 | 0.17 |
| Stochastic Oscillator | 35.42 | 57.21 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Securitize Holdings Inc provides a platform for tokenized real-world assets specializing in tokenizing real-world assets (RWAs) like funds, equities, and fixed income on blockchain networks. The company operates across two primary verticals: i) Tokenization: It consists of on-chain infrastructure and tokenization & distribution, ii) Asset Servicing: It covers post-issuance transfer agent and fund management services. The majority of the company's revenue is derived from the Tokenization vertical.